News
Edwards Lifesciences reports 8% Q1 2025 sales growth to $1.41B, driven by TAVR & TMTT. Discover regulatory catalysts & future growth insights.
Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback